Nxera Pharma Co., Ltd. (SOLTF)
OTCMKTS · Delayed Price · Currency is USD
5.44
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
Nxera Pharma Revenue
Nxera Pharma had revenue of 6.75B JPY in the quarter ending September 30, 2025, a decrease of -27.09%. This brings the company's revenue in the last twelve months to 28.70B, down -1.96% year-over-year. In the year 2024, Nxera Pharma had annual revenue of 28.84B with 125.87% growth.
Revenue (ttm)
28.70B JPY
Revenue Growth
-1.96%
P/S Ratio
2.67
Revenue / Employee
74.74M JPY
Employees
384
Market Cap
517.09M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.84B | 16.07B | 125.87% |
| Dec 31, 2023 | 12.77B | -2.80B | -18.00% |
| Dec 31, 2022 | 15.57B | -2.14B | -12.10% |
| Dec 31, 2021 | 17.71B | 8.87B | 100.32% |
| Dec 31, 2020 | 8.84B | -884.00M | -9.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Nxera Pharma News
- 4 weeks ago - Nxera Pharma Co., Ltd. (SOLTF) Presents at 44th Annual J.P. - Seeking Alpha
- 4 weeks ago - Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa - GlobeNewsWire
- 5 weeks ago - Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties - GlobeNewsWire
- 7 weeks ago - Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia - GlobeNewsWire
- 3 months ago - Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan - GlobeNewsWire
- 3 months ago - Nxera Pharma Co., Ltd. (SOLTF) Discusses R&D Restructuring, Pipeline Prioritization, and Focus on Obesity and Metabolism Transcript - Seeking Alpha
- 3 months ago - Nxera Pharma Shares Video Interviews with Major Shareholders on Its Official YouTube Channel - GlobeNewsWire
- 3 months ago - Nxera Announces Focused Restructuring to Enhance Path to Profitability - GlobeNewsWire